Clopidogrel Tablet, Film Coated
Product Images NDC 72205-199

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 72205-199). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clopidogrel-75mg-100s-blister-crtn-label (Clopidogrel 75mg 100s Blister Crtn Label)

Packaging label for Clopidogrel Tablets, USP 75 mg film-coated tablets by Novadoz Pharmaceuticals LLC. The carton contains 100 unit-dose tablets (10x10). It includes storage instructions, manufacturer details (MSN Laboratories Private Limited, India), and distributor contact information. The label prominently displays the dosage and NDC 72205-199-06.*

FDA Label Image

Clopidogrel-75mg-10s-blister-foil-label (Clopidogrel 75mg 10s Blister Foil Label)

Multiple labels for Clopidogrel 75 mg film-coated tablets by Novadoz Pharmaceuticals LLC. Each label features the product name, strength, a barcode, NDC number 72205-199-11, and manufacturing details including manufacture in India. Space for lot and expiration date is indicated but not filled.*

FDA Label Image

Clopidogrel-75mg-30s-count-cntr-label (Clopidogrel 75mg 30s Count Cntr Label)

Clopidogrel Tablets, USP 75 mg film-coated tablets packaging label. The label includes prescription drug status, NDC 72205-199-30, and instructions for the pharmacist to dispense the medication guide. It lists 30 tablets per package and shows Novadoz Pharmaceuticals LLC as the distributor with MSN Laboratories Private Limited as manufacturer in India. Storage instructions and dosage details are also printed.*

FDA Label Image

Clopidogrel-75mg-500s-count-cntr-label (Clopidogrel 75mg 500s Count Cntr Label)

Label for Clopidogrel Tablets, USP 75 mg film-coated tablets in a package containing 500 tablets. The label includes storage instructions, manufacturer MSN Laboratories Private Limited (India), and distributor Novadoz Pharmaceuticals LLC (Piscataway, NJ). It also provides a pharmacist dispensing note and a website for medication guides.*

FDA Label Image

Clopidogrel-75mg-90s-count-cntr-label (Clopidogrel 75mg 90s Count Cntr Label)

Label for Clopidogrel Tablets, USP 75 mg film-coated tablets by Novadoz Pharmaceuticals LLC. The carton indicates a package of 90 tablets with NDC 72205-199-90. It includes storage instructions, manufacturer information (MSN Laboratories, India), and distributor contact details (Novadoz Pharmaceuticals, NJ, USA). A medication guide advisory for pharmacists is also included.*

FDA Label Image

Figure-1 (Clopidogrel Figure 1)

A horizontal bar chart showing the effect on active metabolite AUC (mean and 90% confidence interval) for clopidogrel when co-administered with various proton pump inhibitors (PPIs): Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. The x-axis represents the change relative to clopidogrel administered alone, ranging from 0.4 to 1.4.*

FDA Label Image

Figure-2 (Clopidogrel Figure 2)

A line graph showing cumulative event rates of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two lines compare event rates for placebo (+ aspirin) and Clopidogrel (+ aspirin), with Clopidogrel showing consistently lower event rates. The graph includes a p-value of 0.00009 and notes other standard therapies were used as appropriate.*

FDA Label Image

Figure-3-cont (Clopidogrel Figure 3 Cont)

A forest plot chart depicting the hazard ratios with 95% confidence intervals for various subgroups comparing Clopidogrel versus placebo. Subgroups include Heparin/LMWH use, Aspirin dosage, GP IIb/IIIa antagonist use, Beta-blocker use, and ACE inhibitor use, as well as overall data. Each subgroup shows sample sizes, number and percentage of events, and the data visually favors Clopidogrel over placebo in several comparisons.*

FDA Label Image

Figure-3 (Clopidogrel Figure 3)

A forest plot chart showing the hazard ratios with 95% confidence intervals comparing Clopidogrel and placebo across various subgroups, including age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke. The horizontal axis displays the hazard ratio scale, with markers indicating favoring Clopidogrel or placebo for each subgroup and overall.*

FDA Label Image

Figure-4 (Clopidogrel Figure 4)

A Kaplan-Meier survival curve chart comparing percent dead before first discharge over 28 days between placebo and clopidogrel groups. The y-axis shows percent dead, and the x-axis shows days since randomization. The chart notes 1845 deaths (8.1%) in the placebo group versus 1726 deaths (7.5%) in the clopidogrel group, indicating a 7% proportional risk reduction (p=0.03).*

FDA Label Image

Figure-5 (Clopidogrel Figure 5)

This chart compares the percentage of patients experiencing death, reinfarction, or stroke before first discharge over 28 days between placebo and Clopidogrel groups. The vertical axis shows the percentage with events, while the horizontal axis shows days since randomization. The graph illustrates a lower event rate for Clopidogrel (9.2%) versus placebo (10.1%), indicating a 9% proportional risk reduction (p=0.002).*

FDA Label Image

Figure-6 (Clopidogrel Figure 6)

A forest plot chart depicting subgroup analyses for Clopidogrel versus placebo effectiveness. The chart presents odds ratios with 99% confidence intervals for various patient subgroups categorized by gender, age at entry, hours since onset, systolic blood pressure, heart rate, and whether a fibrinolytic agent was given. The plot visualizes the relative favorability towards Clopidogrel or placebo for each subgroup and overall.*

FDA Label Image

Figure-7 (Clopidogrel Figure 7)

A line graph depicting the cumulative event rate (%) of fatal or nonfatal vascular events over 36 months of follow-up. Two lines represent outcomes for aspirin and clopidogrel treatments, showing event rates increasing over time, with aspirin slightly higher than clopidogrel. The graph includes a p-value of 0.045 indicating statistical comparison.*

FDA Label Image

Figure-8 (Clopidogrel Figure 8)

A forest plot chart comparing Clopidogrel and Aspirin across qualifying conditions including Stroke, MI, and PAD, showing hazard ratios with 95% confidence intervals. The chart includes data on event counts and percentages for Clopidogrel and Aspirin groups, with markers favoring either Clopidogrel or Aspirin based on hazard ratios.*

FDA Label Image

Structure (Clopidogrel Structure)

Chemical structure of clopidogrel bisulfate, showing its detailed molecular configuration including the sulfur-containing ring, chlorophenyl group, and sulfate component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.